Lv5
1170 积分 2024-04-26 加入
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2个月前
已完结
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
2个月前
已完结
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
2个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
5个月前
已完结
Immunohistochemical Study on Programmed Death Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With the Clinicopathological Parameters
7个月前
已关闭
LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma
7个月前
已完结
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
7个月前
已完结
Immunohistochemical Study on Programmed Death Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With the Clinicopathological Parameters
7个月前
已关闭
MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1
7个月前
已完结
The Prognostic Significance of PD‐L1 Expression and Associated Tumor‐Infiltrating Lymphocytes in Supraglottic Laryngeal Squamous Cell Carcinoma
7个月前
已完结
皖公网安备34019202002308
